occurs in the presence of specificantibodies, the amount of free antigen present is quantified by measuring the light scattered by the conjugate clusters during this inhibition. We report here the application of this method to the detection of antthurnan thyroglobulin (hTg) autoantibodies (aAbs) in human serum. Sera from patients with Hashimoto thyroiditis (8) and Graves disease (9) frequently contain anti-hTg aAbs. However, anti-hTg aAbs may also be found in the serum of healthy subjects (10, 11). Comparative studies of the immune response to thyroid antigens between patients with thyroid disorders and healthy subjects show a qualitative difference between these two groups (12-14). Use of a panel of 15 anti-hTg monoclonal antibodies (mAbs) delineated six antigenic regions on the hTg molecule: I, H, ifi, 1V, V, and VI. Natural aAbs from healthy subjects were found to be polyreactive, with several antigenic regions (ifi, IV, V, and VI), whereas region H was mainly recognized by aAbs from patients with thyroid disorders, especially Hashimoto thyroiditis and Graves disease. On the basis of these results, an immunoradiometric assay of hTg in serum, reliable in the presence of anti-hTg aAbs, was developed (15).
To hydrophilic, polyfunctional spherical microparticles of predetermined diameter, produced by copolymerization of acrylic monomers, we covalently bound human thyroglobulin. The thyroglobulin-microsphere conjugate was agglutinated, in the presence of antimouse immunoglobulins antiserum, by four monoclonal antibodies, each recognizing a different antigenic domain on the thyroglobulin molecule. These agglutinations were quantified by measuring with a specially designed nephelometer the lightscattered by clusters of the conjugates. Agglutination with the monoclonal antibody recognizing antigenic domain II of the thyroglobulin molecule was specifically inhibited by some human sera that contained antithyroglobulin autoantibodies. This allowed us to develop a microparticle-enhanced nephelometnc immunoassay for these autoantibodies with defined epitopic specificity. Using this assay, we detected and quantified antithyroglobulin autoantibodies in serum samples from all eight patients examined with Hashimoto disease and from most (75%) patients with untreated Graves disease. Natural aAbs from healthy subjects were found to be polyreactive, with several antigenic regions (ifi, IV, V, and VI), whereas region H was mainly recognized by aAbs from patients with thyroid disorders, especially Hashimoto thyroiditis and Graves disease. On the basis of these results, an immunoradiometric assay of hTg in serum, reliable in the presence of anti-hTg aAbs, was developed (15) .
In the present report, we used four of these anti-hTg mAbs as the agglutinating reagent for use with a specially synthesized MS-hTg conjugate. We investigated the ability of aAbs to inhibit these MS-hTg agglutinations and subsequently developed a micropar- dilutions (from 50-to 3200-fold) of antimouse 1g.After 1 h at room temperature, the agglutination of the conjugate was quantified by measuring the light scattered, for which we used the specifically designed nephelometer (Nephelia N600; Diagnostics Pasteur) previously described (1). All dilutions and dispensings were performed with the buffer for nephelometry, with use of an automated dilutor (Hamilton Bonaduz AG, Bonaduz, Switzerland).
To inhibit by free hTg the conjugate agglutination observed in the presence of mAb and antimouse Ig, we proceeded as follows: We incubated serial concentrations of hTg ( 
was the greatest inhibition percentage produced by the serum sample, at whatever dilution this was observed; the inhibition was 5%. D5% was the greatest serum dilution that yielded an inhibition of 5%. The lower threshold of 5% was chosen to correspond to a significant decrease of the scattered light measured by the nephelometer, the light scattered at 5% inhibition being 3 SD lower than the mean of the intensity of the light scattered for 0% inhibition. Results of this nephelometric immunoassay were compared with those obtained by IF and PA.
Results

MS-hTg
conjugate.
Polyfunctional hydrophilic MS, 300 nm (SD 12, n = 7 measurements) in diameter, were produced by copolymerization of acrylic monomers; the mean yield was 51% (SD 7%). These MS were covalently coated with hTg through the formation of imine bonds between the primary amino groups of hTg and the MS Effect of serum on MS-hTg conjugate and its agglutination by mAbs. When conjugate was mixed with serial dilutions of human sera (13 sera containing anti-hTg aAbs detected by IF and PA with titers >1:1600, and 50 sera without aAbs), we observed no agglutination inhibited by free hTg. However, two samples containing aAbs and five without aAbs induced a slight agglutination at low dilution. These agglutinations were completely eliminated after incubating the samples with native MS and thus were not specific for the hTg bound on the MS (data not shown). Figure 3 shows the effects of a human serum sample containing anti-hTg aAbs (PA titer, 1:102 400) on agglutination of the conjugates with mAbs and antimouse 1g. The agglutination with mAb 10, which recognizes antigenic domain II on hTg, was largely inhibited by diluted hnnin serum, whereas the other agglutinations observed with mAbs 7,8, and 9 were not altered in the same conditions. We obtained similar results with 6 of the 13 sera containing anti-hTg aAbs, but with none of the 50 samples containing no aAbs. The amount of inhibition was improved by increasing the incubation time of conjugate and inhibiting sera. We thus chose an incubation time of 1 h as providing optimized inhibition. the NIN for each serum sample allowed us to discriminate between positive and negative samples, i.e., to detect aAbs with defined epitopic specificity. Results were considered negative when the NIN could not be computed (i.e., no inhibition was >5% for a 40-fold-diluted sample); NIN 200 (lowest possible value) gave a positive result. Of 158 serum samples, 55(35%) yielded a positive result by nephelom. etry. Anti-hTg aAbs had also been detected in 54 of these 55 sera (98%)-by IF (16 sera), PA (16 sera), or both (22 sera). Samples negative by both IF and PA (37 sera) were mostly negative in the nephelometric assay also (36 sera, 97%). For 17 sera in which aAbs were detected only by PA, the nephelometric assay yielded positive results for 16(94%).
All the results obtained for the 50 patients with a known diagnosis are reported in determinations made with the mAb recognizing the hTg antigenic region II were positive for all eight sera from subjects with Hashimoto thyroiditis, usually with a high N1N value (>5000 for five sera). Anti-hTg aAbs were detected (with NIN <2000) in six of eight (75%) sera samples from subjects with untreated Graves disease and in one serum sample from a hypothyroid subject (low thyrotropin concentration in serum). A positive result was also obtained (NIN <500) for one (evolving Graves disease) of six subjects being treated for Graves disease, for two patients with hyperthyroidism, and for two others with normal results for thyroid hormones.
Dlscuulon
The conjugate obtained by covalent coating of the copolymerized microparticles with hTg reacted with four mAbs, which recognized four different antigenic domains on the hTg molecule (12). Although this reaction was not sufficient to induce agglutination of the conjugate, the secondary reaction of an antimouse Ig with mAbs bound to MS-hTg during the primary reaction produced an agglutination that could be quantified nephelometrically.
Because of this sequence of reactions, the use of such an agglutinating device required a two-step reaction. All conjugate agglutinations were entirely inhibited by free hTg, whatever the mAb used, and could accordingly be considered as specific for the bound hTg. The antimouse Ig thus worked as a detector of the fixation of mAbs on the conjugate.
In the conditions we used to study its immunoreactivity, the conjugate was not specifically agglutinated by serial dilutions of humAn sera containing anti-hTg aAbs (as detected by IF or PA). However, these aAbs reacted with bound hTg, and some of them inhibited the conjugate agglutination observed with one of the four mAbs. Anti-hTg aAbs were usually described as agglutinating aAbs, inducing the agglutination of sensitized erythrocytes or particles in PA. The failure of the conjugate to agglutinate with aAbs or mAbs alone suggested that a threshold of Ig molecules fixed on the conjugate must be reached to induce its agglutination.
This threshold number might not be reached if the epitopes recognized by aAbs or mAbs on the MS-hTg conjugate were not broadly expressed (nonrepetition of these epitopes on the hTg molecule and a small amount of this large molecule bound on each MS). Addition of antimouse Ig to the mixture of conjugate and mAb, which increased the total number of Ig molecules bound per MS. caused the conjugate to agglutinate. Nonagglutination of the conjugate by humnn sera containing aAbs led us to observe their inhibitory effect on the conjugate agglutination with mAbs and xenogenic antimouse 1g.
The irihibitory effect of human sera was found only when mAb 10, recognizing antigenic domain II of hTg, was used in the agglutination process. Inhibition was not observed in agglutinations performed with the three other mAbs (recognizing regions I, Ill, and W). This result suggested a competitive reaction between human aAbs and mAb 10, perhaps by recognition of the same epitope or a nearby epitope in hTg region 11.Because of this competitive reaction and because the affinity of an aAb was perhaps less than that of the mAb, maximum inhibition required a 1-h preincubation step between the MS-hTg and the diluted human sera before the addition of mAb 10. On the basis of these results, we considered the development of a microparticle-enhanced nephelometric immunoassay of anti-hTg aAbs with defined epitopic specificity, by using the mAb 10 to agglutinate the conjugate.
To take best advantage of the inhibition data, we computed for each human serum its NIN, based on the greatest inhibition percentage produced by the serum sample and on the greatest dilution at which inhibition still occurred, i.e., a qualitative and a quantitative component, respectively. NIN In sera from patients with other disorders, these aAbs were observedmore rarely (18%) and always with a low NIN (most often <500). The importance of region 11 of the hTg molecule in autoimmune thyroid disorders was recently confirmed by Henry et al. (22) , who identified a 102-amino acid peptide (hTg region 1149-1250) as an iminunodominant domain in the central part of the hTg molecule. This peptide is recognized by mAb 10 and is also the one most frequently detected by aAbs in autoimmune thyroid diseases.
Previously described as an easy-to-perform method for assaying various antigens in biological fluids (1-7) , the microparticle-enhanced nephelometric immunoassay thus also appears as an appropriate method to detect and quantify anti-hTg aAbs with defined epitopic specifiCity. This new application of the procedure leads the way to an effective development of this methodology in the area of serological diagnosis.
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